Autologous Blood Donor
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Transfusion Service Introduction Blood/Blood Products Requests and Turnaround Time Expectations
Transfusion Service Introduction All blood products and blood components are supplied to UnityPoint Health-Meriter Hospital by the American Red Cross Blood Services. Pathology consultation is available regarding blood and/or components and dosages. ABO and Rho(D)—specific type is used whenever possible for leuko-poor packed cell transfusions. ABO-compatible blood is used for all plasma and platelet components whenever possible. For any orders involving HLA-matched components, the patient must have been HLA typed (sent to the American Red Cross) a minimum of 48 hours prior to intended infusion of the component. HLA typing is only required once. Blood components that are thawed, pooled, washed, volume-reduced, or deglycerolized for a patient will be charged to the patient even if not transfused. The charge is done because these components may not be suitable for another patient. Examples include: Autologous or directed donations Pooled cryoprecipitate 4-hour expiration Thawed fresh frozen plasma 24-hour expiration Thawed cryoprecipitate 6-hour expiration Deglycerolized red cells 24-hour expiration Washed red cells 24-hour expiration All blood components must be completely infused within 4 hours of release from UnityPoint Health-Meriter Laboratories Blood Bank, or be infused within the expiration time. Refer to UnityPoint Health -Meriter’s Blood and Blood Products Transfusion Policy #123 for additional information located on MyMeriter. Blood/Blood Products Requests and Turnaround Time Expectations Requests from UnityPoint Health-Meriter Hospital are entered in the hospital computer system and print in the UnityPoint Health- Meriter Laboratories Blood Bank. For the comfort of the patient, it is important to coordinate collection for other tests with Blood Bank specimens. -
Patient's Guide to Blood Transfusions
Health Information For Patients and the Community A Patient’s Guide to Blood Transfusions Your doctor may order a blood transfusion as part of your therapy. This brochure will focus on frequently asked questions about blood products, transfusions, and the risks and benefits of the blood transfusion. PLEASE NOTE: This information is not intended to replace the medical advice of your doctor or health care provider and is intended for educational purposes only. Individual circumstances will affect your individual risks and benefits. Please discuss any questions or concerns with your doctor. What is a blood transfusion? A blood transfusion is donated blood given to patients with abnormal blood levels. The patient may have abnormal blood levels due to blood loss from trauma or surgery, or as a result of certain medical problems. The transfusion is done with one or more of the following parts of blood: red blood cells, platelets, plasma, or cryoprecipitate. What are the potential benefits of a blood transfusion? If your body does not have enough of one of the components of blood, you may develop serious life-threatening complications. • Red blood cells carry oxygen through your body to your heart and brain. Adequate oxygen is very important to maintain life. • Platelets and cryoprecipitate help to prevent or control bleeding. • Plasma replaces blood volume and also may help to prevent or control bleeding. How safe are blood transfusions? Blood donors are asked many questions about their health, behavior, and travel history in order to ensure that the blood supply is as safe as it can be. Only people who pass the survey are allowed to donate. -
Patient Information Leaflet – Plasma Exchange Procedure
Therapeutic Apheresis Services Patient Information Leaflet – Plasma Exchange Procedure Introduction Antibodies, which normally help to protect you from infection, can begin to attack your own This leaflet has been written to give patients healthy cells, or an over production of proteins can information about plasma exchange (sometimes cause your blood to become thicker and slow down called plasmapheresis). If you would like any more the blood flow throughout your body. A plasma information or have any questions, please ask the exchange can help improve your symptoms, doctors and nurses involved in your treatment at although this may not happen immediately. the NHS Blood and Transplant (NHSBT) Therapeutic Apheresis Services Unit. Although plasma exchange may help with symptoms, it will not normally cure your condition When you have considered the information given as it does not switch off the production of the in this leaflet, and after we have discussed the harmful antibodies or proteins. It is likely that procedure and its possible risks with you, we will this procedure will form only one part of your ask you to sign a consent form to indicate that you treatment. are happy for the procedure to go ahead. Before any further procedures we will again check that you are happy to proceed. How do we perform Plasma Exchange? What is a plasma exchange? Plasma exchange is performed using a machine Blood is made up of red cells, white cells and called a Blood Cell Separator which can separate platelets which are carried around in fluid called blood into its various parts. The machine separates plasma. -
FACTS ABOUT DONATING Blood WHY SHOULD I DONATE BLOOD? HOW MUCH BLOOD DO I HAVE? Blood Donors Save Lives
FACTS ABOUT DONATING BLOOD WHY SHOULD I DONATE BLOOD? HOW MUCH BLOOD DO I HAVE? Blood donors save lives. Volunteer blood donors provide An adult has about 10–11 pints. 100 percent of our community’s blood supply. Almost all of us will need blood products. HOW MUCH BLOOD WILL I donate? Whole blood donors give 500 milliliters, about one pint. WHO CAN DONATE BLOOD? Generally, you are eligible to donate if you are 16 years of WHAT HAPPENS TO BLOOD AFTER I donate? age or older, weigh at least 110 pounds and are in good Your blood is tested, separated into components, then health. Donors under 18 must have written permission distributed to local hospitals and trauma centers for from a parent or guardian prior to donation. patient transfusions. DOES IT HURT TO GIVE BLOOD? WHAT ARE THE MAIN BLOOD COMPONENTS? The sensation you feel is similar to a slight pinch on the Frequently transfused components include red blood arm. The process of drawing blood should take less than cells, which replace blood loss in patients during surgery ten minutes. or trauma; platelets, which are often used to control or prevent bleeding in surgery and trauma patients; and HOW DO I PREPARE FOR A BLOOD DONATION? plasma, which helps stop bleeding and can be used to We recommend that donors be well rested, eat a healthy treat severe burns. Both red blood cells and platelets meal, drink plenty of fluids and avoid caffeine and are often used to support patients undergoing cancer alcohol prior to donating. treatments. WHAT CAN I EXPECT WHEN I DONATE? WHEN CAN I DONATE AGAIN? At every donation, you will fill out a short health history You can donate whole blood every eight weeks, platelets questionaire. -
Terminology Resource File
Terminology Resource File Version 2 July 2012 1 Terminology Resource File This resource file has been compiled and designed by the Northern Assistant Transfusion Practitioner group which was formed in 2008 and who later identified the need for such a file. This resource file is aimed at Assistant Transfusion Practitioners to help them understand the medical terminology and its relevance which they may encounter in the patient’s medical and nursing notes. The resource file will not include all medical complaints or illnesses but will incorporate those which will need to be considered and appreciated if a blood component was to be administered. The authors have taken great care to ensure that the information contained in this document is accurate and up to date. Authors: Jackie Cawthray Carron Fogg Julia Llewellyn Gillian McAnaney Lorna Panter Marsha Whittam Edited by: Denise Watson Document administrator: Janice Robertson ACKNOWLEDGMENTS We would like to acknowledge the following people for providing their valuable feedback on this first edition: Tony Davies Transfusion Liaison Practitioner Rose Gill Transfusion Practitioner Marie Green Transfusion Practitioner Tina Ivel Transfusion Practitioner Terry Perry Transfusion Specialist Janet Ryan Transfusion Practitioner Dr. Hazel Tinegate Consultant Haematologist Reviewed July 2012 Next review due July 2013 Version 2 July 2012 2 Contents Page no. Abbreviation list 6 Abdominal Aortic Aneurysm (AAA) 7 Acidosis 7 Activated Partial Thromboplastin Time (APTT) 7 Acquired Immune Deficiency Syndrome -
Summary of Blood Donor Deferral Following COVID-19 Vaccine And
Updated 04 14 2021 Updated Information from FDA on Donation of CCP, Blood Components and HCT/Ps, Including Information on COVID-19 Vaccines, Treatment with CCP or Monoclonals 1) HCT/P DONOR ELIGIBILITY: For the agency’s current thinking on HCT/P donation during the pandemic, including donor eligibility following vaccination to prevent COVID-19, refer to FDA’s January 4th Safety and Availability communication, Updated Information for Human Cell, Tissue, or Cellular or Tissue-based Product (HCT/P) Establishments Regarding the COVID-19 Pandemic. 2) CCP and ROUTINE BLOOD DONOR ELIGIBILITY: 2-1. Blood donor eligibility following COVID-19 vaccine Blood donor deferral following COVID-19 vaccines is not required. Consider the following information on FDA’s web page Updated Information for Blood Establishments Regarding the COVID-19 Pandemic and Blood Donation last updated 01/19/21” – see the full document on page 2 below. The blood establishment’s responsible physician must evaluate prospective donors and determine eligibility (21 CFR 630.5). The donor must be in good health and meet all donor eligibility criteria on the day of donation (21 CFR 630.10). The responsible physician may wish to consider the following: o individuals who received a nonreplicating, inactivated, or mRNA-based COVID-19 vaccine can donate blood without a waiting period, o individuals who received a live-attenuated viral COVID-19 vaccine, refrain from donating blood for a short waiting period (e.g., 14 days) after receipt of the vaccine, o individuals who are uncertain about which COVID-19 vaccine was administered, refrain from donating for a short waiting period (e.g., 14 days) if it is possible that the individual received a live-attenuated viral vaccine. -
Laboratory Best Transfusion Practice for Neonates, Infants and Children
Laboratory Best Transfusion Practice for Neonates, Infants and Children This summary guidance should be used in conjunction with the appropriate 20161 and 20122 BSH Guidelines and laboratory SOPs Compatibility testing Neonates and infants < 4 months Obtain neonatal and maternal transfusion history (including any fetal transfusions) for all admissions. Obtain a maternal sample for initial testing where possible, in addition to the patient sample. Red cell selection: no maternal antibodies present Select appropriate group and correct neonatal specification red cells. Group O D-negative red cells may be issued electronically without serological crossmatch. If the laboratory does not universally select group O D-negative red cells for this age group, blood group selection should either be controlled by the LIMS or an IAT crossmatch should be performed using maternal or neonatal plasma to serologically confirm ABO compatibility with both mother and neonate. Red cell selection: where there is maternal antibody Select appropriate group red cells, compatible with maternal alloantibody/ies. An IAT crossmatch should be performed using the maternal plasma. If it is not possible to obtain a maternal sample it is acceptable to crossmatch antigen-negative units against the infant’s plasma. Where paedipacks are being issued from one donor unit it is only necessary to crossmatch the first split pack. Subsequent split packs from this multi-satellite unit can be automatically issued without further crossmatch until the unit expires or the infant is older than 4 months. If packs from a different donor are required, an IAT crossmatch should be performed. Infants and children ≥ 4 months For infants and children from 4 months of age, pre-transfusion testing and compatibility procedures should be performed as recommended for adults. -
Cord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights • Umbilical cord blood, like bone marrow and peripheral blood, is a rich source of stem cells for transplantation. There may be advantages for certain patients to have cord blood stem cell transplants instead of transplants with marrow or peripheral blood stem cells (PBSCs). • Stem cell transplants (peripheral blood, marrow or cord blood) may use the patient’s own stem cells (called “autologous transplants”) or use donor stem cells. Donor cells may come from either a related or unrelated matched donor (called an “allogeneic transplant”). Most transplant physicians would not want to use a baby’s own cord blood (“autologous transplant”) to treat his or her leukemia. This is because donor stem cells might better fight the leukemia than the child’s own stem cells. • Cord blood for transplantation is collected from the umbilical cord and placenta after a baby is delivered. Donated cord blood that meets requirements is frozen and stored at a cord blood bank for future use. • The American Academy of Pediatrics’s (AAP) policy statement (Pediatrics; 2007;119:165-170.) addresses public and private banking options available to parents. Among several recommendations, the report encourages parents to donate to public cord blood banks and discourages parents from using private cord blood banks for personal or family cord blood storage unless they have an older child with a condition that could benefit from transplantation. • The Stem Cell Therapeutic and Research Act of 2005 put several programs in place, including creation of the National Cord Blood Inventory (NCBI) for patients in need of transplantation. -
Getting Ready for Apheresis
Page 1 of 2 Getting Ready for Apheresis For Patients What is apheresis? How does it work? Apheresis [AY-fur-EE-sis] is the removal of certain • You will sit in a chair or lie in a bed. blood cells. • We place a needle in the vein of each arm. We We take blood from your vein and pass it through a remove blood from one arm and pass it through machine. The machine collects a part of your blood. a machine. The rest of the blood is returned to your body. • As the blood leaves your body, it is treated There are several types of apheresis. Your doctor will with medicines (citrate and heparin) to tell you which type you will have: prevent clotting. ☐ Red blood cell exchange removes some of your • The machine spins, separating the parts of the red blood cells. These are replaced by a donor’s blood. This allows us to collect the needed cells. red blood cells. This takes 2 to 3 hours. • The rest of the blood flows back into your body ☐ Plasma exchange removes plasma from your through the needle in your other arm. blood. The plasma is replaced with a donor’s plasma, 5% albumin (a protein) or both. This If your veins are too small for needles, you may need takes 2 to 3 hours. to have a catheter (a tiny tube) placed into a larger vein. The vein is usually in the lower neck, upper ☐ Plateletpheresis removes some of your platelets chest or groin (area between your leg and trunk). -
When Is Blood Donation Safe? T Lise Sofie H
Transfusion and Apheresis Science 58 (2019) 113–116 Contents lists available at ScienceDirect Transfusion and Apheresis Science journal homepage: www.elsevier.com/locate/transci Review ☆ Donor health assessment – When is blood donation safe? T Lise Sofie H. Nissen-Meyera, Jerard Seghatchianb a Oslo Blood Centre, Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway b International Consultancy in Blood Components Quality/Safety Improvement and DDR Strategies, London, United Kingdom ARTICLE INFO ABSTRACT Keywords: Blood donation is a highly regulated practice in the world, ensuring the safety and efficacy of collected blood and its Blood donation components whether used as irreplaceable parts of modern transfusion medicine, as a therapeutic modality or addi- Donor health assessment tional support to other clinical therapies. In Norway blood donation is regulated by governmental regulations Health and disease (“Blodforskriften”) and further instructed by national guidelines, “Veileder for transfusjonstjenesten” [1], providing an Transfusion aid for assessment of donor health. This concise review touches upon: definitions of donor health and disease; some Blood components important pitfalls; and the handling of some common and less common pathophysiological conditions; with an example from the Blood center of Oslo University Hospital, Norway’s largest blood center. I also comment on some medications used by a number of blood donors, although wounds, ulcers and surgery are not included. Considering the panorama of conditions blood donors can suffer from, blood donation can never be completely safe for everybody, as zero riskdoes not exist, but it is our task through donor evaluation to identify and reduce risk as much as possible. 1. -
Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods
Guidance for Industry Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods Additional copies of this guidance document are available from: Office of Communication, Training and Manufacturers Assistance (HFM-40) 1401 Rockville Pike, Rockville, MD 20852-1448 (Tel) 1-800-835-4709 or 301-827-1800 (Internet) http://www.fda.gov/cber/guidelines.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (CBER) January 2001 Technical Correction February 2001 TABLE OF CONTENTS Note: Page numbering may vary for documents distributed electronically. I. INTRODUCTION ............................................................................................................. 1 II. BACKGROUND................................................................................................................ 1 III. CHANGES FROM THE DRAFT GUIDANCE .............................................................. 2 IV. RECOMMENDED DONOR SELECTION CRITERIA FOR THE AUTOMATED RED BLOOD CELL COLLECTION PROTOCOLS ..................................................... 3 V. RECOMMENDED RED BLOOD CELL PRODUCT QUALITY CONTROL............ 5 VI. REGISTRATION AND LICENSING PROCEDURES FOR THE MANUFACTURE OF RED BLOOD CELLS COLLECTED BY AUTOMATED METHODS.................. 7 VII. ADDITIONAL REQUIREMENTS.................................................................................. 9 i GUIDANCE FOR INDUSTRY Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods This -
Points to Consider in the Preparation and Transfusion of COVID-19 Convalescent Plasma
Points to consider in the preparation and transfusion of COVID-19 convalescent plasma Jay Epstein1 & Thierry Burnouf2 On behalf of the ISBT Working Party on Global Blood Safety 1 US Food and Drug Administration, Silver Spring, MD, USA 2 College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan Important notices: • Because the safety and efficacy of convalescent COVID-19 plasma as a treatment for COVID- 19 are unproven at this time, clinical use of this product should be managed as an experimental therapy consistent with ethical and legal safeguards (informed consent of donors and patients, institutional approval, special labeling as an investigational product, compliance with applicable regulatory requirements). • Ideally, COVID-19 plasma should be used in the context of an organized research study designed to determine its safety and efficacy in comparison with standard of care or other therapeutic interventions. Even if used empirically it is vital to ensure monitoring of patient outcomes including clinical and laboratory indicators of safety and efficacy to maximize the knowledge that might be gained. • Collection and retention of blood specimens from both donors and recipients (pre- and post- treatment) should be performed to permit retrospective determination of the characteristics of an effective product and dosage regimen, and the characteristics of patients most likely to benefit. • General information on the rationale and approach to use of convalescent plasma in virus epidemics can be found in the “WHO Blood Regulators Network (2017) Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus.” (1) Intentional collection of convalescent plasma should be performed only by apheresis in order to avoid unnecessary red cell loss in the donor and to optimize the volume of plasma that can be generated for investigational use.